Jerry Parrott is President, Chief Executive Officer and a Director of BioMarker Strategies. Mr. Parrott previously served Human Genome Sciences as Vice President, Corporate Affairs and Public Policy from 2001 until the acquisition of HGS by GlaxoSmithKline in 2012. He formerly held senior public policy, corporate affairs, and other positions with Bristol-Myers Squibb Company, American Hospital Supply Corporation and Walgreen Company. As Principal of Policy Advocates Inc. from 1995-2001, Mr. Parrott’s clients included HGS, Bristol-Myers Squibb, Ciba-Geigy, Diversa, Genentech, HealthCare Ventures, Hoffmann-La Roche, Western Digital, Wyeth and others. During this period, he helped take public 3-Dimensional Pharmaceuticals, subsequently acquired by Johnson & Johnson, and InforMax, subsequently acquired by Invitrogen. He has helped launch important therapeutic products in immunology, oncology, infectious disease and pain relief, and has helped bring two prescription products over the counter.
Since 2006, Mr. Parrott has served as Chairman and President of Maryland Health Care Product Development Corporation, a nonprofit venture capital fund committed to helping health care products companies grow and succeed in Maryland. He is a Director of Noxilizer Inc., MdBio, and the Tech Council of Maryland, and Senior Advisor to the Maryland Life Sciences Advisory Board. He formerly served as Chair of the Biotechnology Industry Organization (BIO) Committee on Outreach and Alliance Development, Chair of the Rx Partners health care reform coalition, Founding Director of BioHealth Innovation, Founding Trustee of the Foundation for Genetic Medicine, and Trustee of the Committee for Economic Development.
Dr. Greg Bertenshaw, is Vice President, Research & Development. He is responsible for development of the SnapPath® Cancer Diagnostics System and PathMAP® Functional Signaling Profiles. He is also Principal Investigator on all of the National Cancer Institute (NCI) grants and contracts awarded to our Company since the beginning of 2013. This includes the new Phase I NCI contract announced in September 2016, which funds development of initial proof-of-concept data for a potential companion diagnostic to predict individual patient response to immunotherapies for the treatment of non-small cell lung cancer. It also includes the recently awarded Phase I/II NCI Fast Track Grant we announced in June 2016. The Grant announced in June is focused on targeted therapies, and funds development of a different PathMAP® NSCLC companion diagnostic to facilitate selection of optimal therapy for patients with non-small cell lung cancer. It provides for a 2-year $2 million Phase II grant that will begin after we achieve our proposed milestones under a 6-month $300,000 Phase I grant. Dr. Bertenshaw is also Principal Investigator on our ongoing NCI Phase II contract to develop PathMAP® Melanoma as a companion diagnostic to facilitate selection of optimal therapy for patients with melanoma.
Before joining BioMarker Strategies, Dr. Bertenshaw was Director of New Technology at Correlogic Systems, Inc., a biomarker discovery company developing in vitro diagnostic tests for ovarian, breast, prostate and colorectal cancers. In particular, Dr. Bertenshaw worked with a multidisciplinary team to develop an immunoassay Luminex-based ovarian cancer diagnostic test (OvaCheck™). Dr. Bertenshaw was involved in all phases of the development from the biomarker discovery phase through submission to the Food and Drug Administration. Dr. Bertenshaw holds a Ph.D. in Biochemistry and Molecular Biology from the Pennsylvania State University College of Medicine, and a B.S. in Biochemistry from University of Manchester, Manchester, United Kingdom.
Jack Davis is Director and Chairman, BioMarker Strategies. He brings more than forty years of experience forming and leading companies in the molecular diagnostics, pathology, and clinical laboratory industries. Mr. Davis has a track record of success bringing breakthrough technologies and tests to the market for the benefit of cancer patients.
Mr. Davis’ professional career includes serving as a co-founder, President/COO and later CEO, and Chairman of Dianon Systems, Inc., which he helped build from a venture capital backed start-up to a leading provider of Clinical and Anatomic Pathology based solutions for clinicians. Dianon was purchased by LabCorp in 2003 for $600 m. In addition, he served as President and CEO of Calypte Biomedical, a biodiagnostics company that developed the first urine-based HIV test, where he shepherded the company through its IPO. Previously, he was the Division Vice President and General Manager of the $100 m worldwide Diagnostic Products business unit of Abbott Diagnostics.
Mr. Davis has also served on the Board of Directors of over twelve companies, including HistoRx, RedPath Integrated Pathology and Asterand. Over the course of his career, he has taken two companies public as CEO and sold three other companies as either Chairman or Director.
Scott Allocco is Director, Co-Founder, and Former President of BioMarker Strategies. He is President, SJA Healthcare Strategies. As a member of the Personalized Medicine Coalition (PMC), and Personalized Medicine Committee, he is actively engaged in efforts to reform FDA and CMS regulatory and reimbursement policies for next generation biomarker tests. He is the co-chair of the BIO Personalized Medicine committee and the former co-chair of the Personalized Medicine Coalition's Task Force on CMS Coverage, Coverage and Reimbursement Reform. Prior to co-founding BioMarker Strategies, he had 15 years of healthcare and pharmaceutical industry experience, including drug coverage and reimbursement issues for commercial and public sector health insurance programs. Most recently, Mr. Allocco was vice president of state government relations for Coventry Health Care, one of the nation's largest health insurance companies. He was also vice president for business development at First Health Services, a Coventry subsidiary which he helped build into the nation's largest pharmacy benefits administrator of Medicaid drug-benefit programs.
Prior to joining First Health Services, Allocco was a managing director in the health-care practice group at Hill and Knowlton's Washington, D.C. office. He also served for four years as the director of the Office of Government Affairs for the New Jersey Department of Health and Senior Services under Governor Christine Todd Whitman. He graduated cum laude with a B.A. in public policy from Hamilton College.
Dr. Douglas P. Clark is Director, Scientific Founder, and Former Acting CEO and Former CMO of BioMarker Strategies. He was recently named Chairman of the Pathology Department of the University of New Mexico Health Sciences Center. From 2011-2013, he served as CMO and Acting CEO of BioMarker Strategies and as an adjunct Professor of Pathology and Oncology at The Johns Hopkins Medical Institutions, where he served as the director of the Division of Cytopathology from 2002-2010. He is a board-certified anatomic pathologist and cytopathologist with experience in oncology, microbiology and molecular diagnostics. He serves on the editorial boards of Cancer Cytopathology and Expert Review of Molecular Diagnostics.
Dr. Clark has been at the forefront of efforts to integrate molecular biomarkers into the field of pathology. At the University of New Mexico, he will spearhead efforts to expand translational and personalized medicine initiatives. At Johns Hopkins, he successfully developed a comprehensive molecular cytopathology program that serves as a vital resource to clinical trial development, particularly in the area of oncology. This work has led to numerous publications and a pending patent for a targeted therapy-related diagnostic test that has been licensed by BioMarker Strategies. Dr. Clark received his M.D. degree from The Johns Hopkins School of Medicine and his B.A. degree in biochemistry and molecular biology from Northwestern University.
Katarzyna Kusmierz is a Director of BioMarker Strategies and Chairman of the Supervisory Board and Chief Executive Officer of USP Group, which includes USP Zdrowie, Poland’s leading OTC/Consumer Health pharmaceutical company. USP Zdrowie product lines include Cold & Flu, Pain, Energy, Digestive Health, Joint Relief and other indications. A number of the USP Zdrowie products are the leaders of their categories in Poland. Ms. Kusmierz has been with USP Group almost since its creation 20 years ago. She has held a series of operational and supervisory roles of increasing responsibility, and worked with USP Group Founders on corporate structure, tax and regulatory issues, as well as financial and strategic planning. She also serves as President of US Pharmacia International, Inc., which is the center of the company’s U.S. operations, as well as financial and legal headquarters of the USP Group. In her capacity as Chairman of the Supervisory Board, Ms. Kusmierz helped define USP Group’s mission and vision as a promotor of health and wellness among Polish consumers. A major element of this was the rebranding campaign that led to the creation of USP Zdrowie, Polish for Health – one of the most recognizable names in pharmaceuticals among consumers in Poland. Ms. Kusmierz has also led USP Group to expand its efforts into investing into early stage biotech companies through its US investing entity, Novit LP, as well as in Poland through another affiliated entity, and sees such investments as a significant part of the Group’s growth plans going forward. She studied at the Department of Economics at the University of Gdansk, Poland, focusing on international trade.
Dr. Glenn Miller, Chair of the Scientific Advisory Board and Director, BioMarker Strategies, was most recently Chief Technology Officer and Executive Vice President of MolecularMD, which develops and commercializes specialty molecular diagnostics for oncology applications. He formerly served as Vice President and Head of Strategy for Personalized Medicine and Biomarkers at AstraZeneca. Prior to joining AstraZeneca, he was Vice President and General Manager of Genzyme Analytical Services, a division of Genzyme Genetics, one of the five largest clinical laboratories in the US, which was acquired for $925 million by LabCorp in 2010. Dr. Miller was a key member of the team charged with the divestiture of the Genzyme Genetics business, as well as its subsequent integration into LabCorp. The customers of Genzyme Genetics included 23 of the world’s 25 largest pharmaceutical companies and over 50 biotechnology companies.
After being named Scientific Director of Genzyme Genetics in 2001, Dr. Miller’s responsibilities included positions leading R&D efforts, technology evaluation to identify next-generation testing platforms, and oversight of all academic and scientific collaborations. Dr. Miller was previously responsible for developing pharmacogenetics and biomarker development for a wide variety of drug development programs within Genzyme Corporation.
Dr. Miller has published and spoken extensively on genetics, pharmacogenomics and personalized medicine. He has served as Chair of the Personalized Medicine Task Force of the European Federation of Pharmaceutical Industry Associations, and is a member of the Clinical Sciences Committee of the Personalized Medicine Coalition.
Dr. Miller received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo. He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami School of Medicine.